Stock AnalizXeris Biopharma Holdings, Inc. XERS
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Xeris Biopharma Holdings, Inc. (XERS) is a healthcare company listed in the US with a market value of about $3.0B. In the twelve months to September 30, 2026 it had revenue of $368M and net income of -$6M, a net margin of -1.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 41.9, 5-year revenue growth of 70% a year, a 5-year average ROIC of -24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 57% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $368M | $292M | $203M | $164M | $110M | $50M | $20M |
| Net income | -$6M | $554000 | -$55M | -$62M | -$95M | -$123M | -$91M |
| Free cash flow | $73M | — | — | — | — | -$97M | -$81M |
| EPS (diluted) | $-0.04 | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-2.14 |
| Net margin | -1.8% | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% |
| ROIC | — | 9.2% | -13.4% | -19.4% | -33.2% | -62.8% | -54.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $17.29, 4% above the current price; targets range from $12.00 to $21.00; the consensus rating is “Strong buy”; expected EPS is $-0.01 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Xeris Biopharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 57% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Xeris Biopharma pay a dividend?
Not currently.
Is Xeris Biopharma a good stock to buy?
We do not give buy or sell advice. Xeris Biopharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.